DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 017768/S-041

SUPPLEMENT APPROVAL

Molnlycke Health Care US, LLC
Attention: Curtis Truesdale
5550 Peachtree Parkway
Suite 500
Norcross, GA 30092

Dear Mr. Truesdale:

Please refer to your Supplemental New Drug Application (sNDA) dated January 30, 2014, received on January 31, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Hibiclens (4% w/v chlorhexidine gluconate) solution.

We acknowledge receipt of your amendments dated April 8, and May 30, 2014.

This "Changes Being Effected" sNDA provides for the addition of a sterility statement to the 15-milliliter size, and removal of the patient preoperative skin preparation indication and associated labeling from all but the 15-milliliter size.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling (FPL) as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the following labeling submitted on January 30, 2014:

- 15-milliliter immediate container (packette)
- 8-ounce immediate container
- 16-ounce immediate container
- 32-ounce immediate container

and the following labeling submitted on May 30, 2014:

- 50-count outer carton for 15-milliliter packettes
- 4-ounce immediate container
- 1-gallon immediate container

Submit the FPL in the "Drug Facts" format (21 CFR 201.66), where applicable.

The FPL should be submitted electronically according to the guidance for industry titled "Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)." Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 017768/S-041."** Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Celia Peacock, Regulatory Project Manager at (301) 796-4154.

Sincerely,

{See appended electronic signature page}

Theresa Michele, M.D.
Director
Division of Nonprescription Clinical Evaluation
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE:
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DANIEL BRUM
06/30/2014
Signed on behalf of Dr. Theresa Michele